How Will the Market React to Jazz Pharmaceuticals PLC (JAZZ) Stock Getting a Bearish Rating

Jazz Pharmaceuticals PLC (JAZZ) stock is lower by 3.48% over the past week and gets a Bearish rating from InvestorsObserver Sentiment Indicator.

Jazz Pharmaceuticals PLC has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on JAZZ!

See Full JAZZ Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With JAZZ Stock Today?

Jazz Pharmaceuticals PLC (JAZZ) stock is trading at $131.64 as of 2:46 PM on Wednesday, Oct 12, a drop of -$1.82, or -1.36% from the previous closing price of $133.46. The stock has traded between $130.74 and $134.05 so far today. Volume today is less active than usual. So far 161,234 shares have traded compared to average volume of 604,539 shares. To see InvestorsObserver's Sentiment Score for Jazz Pharmaceuticals PLC click here.

More About Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy. Click Here to get the full Stock Report for Jazz Pharmaceuticals PLC stock.